📰 Escalation Study News
Page 3 - Escalation Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Escalation Study. Real-time updates on events, politics, business and more.
May 12, 2022
ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today... | May 12, 2022
April 8, 2022
/PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that...
December 15, 2021
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
December 13, 2021
Phase 1b results of teclistamab in combination with DARZALEX? (daratumumab) subcutaneous (SC) also presented at ASH 2021 Annual Meeting1,2 The Janssen Pharmaceutical Companies of Johnson Johnson
December 11, 2021
- Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with Relapsed/Refractory NHL, including DLBCL and FL, and...
December 7, 2021
The Omicron variant concerns were front and center in the markets in the week ended Dec. 3, and ...
November 4, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
June 4, 2021
119 Abstracts and Presentations Featuring Sarah Cannon's Clinical Research and Care Insights Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society
May 20, 2021
Share: Cohort expansion in mCRPC: 11/22 (50%) patients have ≥ 50% PSA reduction; anti-tumor activity observed in four of seven patients evaluated (including one unconfirmed partial response) Conference call and webcast with external guest presenters on Friday, June 4, 2021 at 4:30 P.M. ET ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics fo...
May 19, 2021
Share this article Share this article SOUTH SAN FRANCISCO, Calif., May 19, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced additional data from the Companys dose-escalation cohort of the Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting ant...